About the Authors

John J. Alam

Roles Conceptualization, Formal analysis, Funding acquisition, Methodology, Project administration, Supervision, Visualization, Writing – original draft, Writing – review & editing

jalam@eippharma.com

Affiliation EIP Pharma, Inc., Boston, Massachusetts, United States of America

Michael Krakovsky

Roles Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Validation, Writing – review & editing

Affiliation Pharmaseed Ltd., Ness-Ziona, Israel

Ursula Germann

Roles Formal analysis, Visualization, Writing – original draft, Writing – review & editing

Affiliation EIP Pharma, Inc., Boston, Massachusetts, United States of America

Aharon Levy

Roles Methodology, Writing – review & editing

Affiliation Pharmaseed Ltd., Ness-Ziona, Israel

Competing Interests

I have read the journal's policy and the authors of this manuscript have the following competing interests: John Alam is the scientific founder and CEO of EIP Pharma, Inc., a private company based in Cambridge, Massachusetts, USA, that provided funding for these studies and is developing neflamapimod (VX-745) as a potential treatment for CNS disorders. Michael Krakovsky and Aharon Levy are employees of Pharmaseed Ltd., the pre-clinical laboratory contracted by EIP Pharma, Inc. to conduct the studies in this report. Ursula Germann is scientific advisor to EIP Pharma, Inc. for neflamapimod research studies. This does not alter our adherence to PLOS ONE policies on sharing data and materials.